Regeneron Pharmaceuticals (REGN) 10-K Summary — Year Ended Dec 31, 2023
Regeneron Pharmaceuticals reported an increase in revenue for the year, with operating income and net income at the same level and operating cash flow higher than net income. The company faces manufacturing expansion risks and is investing in additional capabilities.
Key takeaway
Year ended Dec 31, 2023 · FY2025 10-K
Regeneron Pharmaceuticals reported an increase in revenue for the year, with operating income and net income at the same level and operating cash flow higher than net income. The company faces manufacturing expansion risks and is investing in additional capabilities.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$13.1B
Revenue reported for the fiscal year.
Operating income
$4B
Income from operations reported for the year.
Net income
$4B
Net income reported for the year.
Operating cash flow
$4.6B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2021 | $16.1B | n/a |
| Dec 31, 2022 | $12.2B | -24.3% |
| Dec 31, 2023 | $13.1B | +7.8% |
Business overview
The company develops and manufactures drugs using its Trap and VelociSuite technologies, and is also exploring siRNA gene silencing, genome editing, and viral-based gene delivery. It collaborates with partners and operates manufacturing facilities that must comply with regulatory requirements.
Financial performance
Revenue increased after a decline in the prior year. Operating income and net income were reported at the same amount, while operating cash flow exceeded net income.
Material risks
Material risks include difficulties in scaling up manufacturing, such as process development hurdles, yield variability, and the need to hire and train qualified personnel. The company also faces regulatory compliance risks for its facilities and may encounter delays or cost overruns in acquiring production equipment.
Liquidity and capital
The company expects significant capital expenditures for manufacturing expansion and may need to develop or acquire additional manufacturing capabilities. It is also hiring and training employees to support its growing operations.
What to watch
Monitor the company's progress in expanding manufacturing facilities and any related regulatory approvals or delays.